NicOx

Nicox S.A.
Company type	Société Anonyme
Traded as	Euronext: COX
Industry	research and development in biotechnology
Founded	1996
Headquarters	Sophia Antipolis, France
Website	www.nicox.com

Nicox S.A. is a French ophthalmology company developing treatments to maintain vision and improve ocular health.^[1] Nicox is headquartered in Sophia Antipolis, France, and its Chairman and CEO is Michele Garufi.^[2]^[3]

Nicox is listed on Euronext Paris^[4] (Compartment B: Mid-Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. Its pipeline includes three programs in development, and it has two U.S. Food and Drug Administration (FDA) approved products.^[5]

^ "COX: Nicox Stock Price Quote - EN Paris - Bloomberg". Bloomberg News.
^ "Here's a French Biotech Investors May Not Care About Enough". Bloomberg.com. Retrieved 2018-08-08.
^ "Michele Garufi, PDG de NicOx".
^ "| live".
^ "Nicox S.A. (NICXF) Stock Price Today, Quote & News | Seeking Alpha".

[1] "COX: Nicox Stock Price Quote - EN Paris - Bloomberg". Bloomberg News.

[2] "Here's a French Biotech Investors May Not Care About Enough". Bloomberg.com. Retrieved 2018-08-08.

[3] "Michele Garufi, PDG de NicOx".

[4] "| live".

[5] "Nicox S.A. (NICXF) Stock Price Today, Quote & News | Seeking Alpha".

[1]

[2]

[3]

[4]

[5]